Gaps in hepatitis testing and monitoring programmes across the EU/EEA

May 31, 2017, European Centre for Disease Prevention and Control (ECDC)
In the EU/EEA, we see a wide variation in existing national testing policy and practice when it comes to hepatitis B and C but most countries reported more than one type of approach to the funding of HBV/HCV testing. Credit: European Centre for Disease Prevention and Control, ECDC

The survey results suggest a wide variation in existing national testing policy and practice when it comes to hepatitis B and C - with overall limited monitoring of testing, diagnosis, and treatment across EU/EEA Member States. Many respondents expressed a need for Europe-wide practical guidance on how testing initiatives should be conducted, evaluated, and monitored.

An estimated 9 to 10 million Europeans have been infected with the hepatitis B (HBV) or hepatitis C virus (HCV) in the countries of the European Union and European Economic Area (EU/EEA), and many are unaware of their infection. ECDC undertook two surveys to evaluate needs and priorities to inform a Guidance on HBV/HCV testing and screening in the EU and to assess the availability of data on the HBV and HCV epidemic against the core indicators defined in the WHO Regional Action Plan to eliminate viral hepatitis by 2030. 20 (65%) and 21 (68%) Member States responded to the two surveys.

The results suggest a wide variation in HBV/HCV testing policy and practice across the EU/EEA showing significant gaps in available testing and a lack of national monitoring programmes regarding all aspects of testing, diagnosis, treatment, morbidity, and mortality.

Less than half of the responding EU/EEA countries have dedicated HBV or HCV testing guidance in place (29% and 48% respectively), with the remainder having either a number of policy documents where HBV/HCV is included, or no testing policy at all. Just more than half of the countries had a policy on testing of HBV/HCV among people who inject drugs in place, while other key groups such as commercial sex workers, me who have sex with men and people receiving tattoos or piercings in unregulated settings were mostly omitted.

A need for European-level guidance

At the implementation level, more than three out of four responding countries reported that they felt that risk groups were not targeted effectively by existing testing programmes. Just over half of responding countries agreed that there is a need for a new European-level testing guidance, in particular guidance on who to , how to target those at risk, and monitoring and evaluation of testing initiatives.

With regards to monitoring indicators, almost all the responding countries collected some morbidity and mortality data on hepatitis B and C's long term complication, liver cancer.

However data on the HBV or HCV status of the patient was recorded by only a few. The most frequently monitored indicator for HCV was the number of people undergoing treatment (12 countries), whereas the number of those treated for HBV is only monitored in seven countries.

What is more: there are no indicators for hepatitis B or C infection that are monitored routinely by all responding Member States, meaning that further work would be required before any meaningful EU-wide monitoring can be established.

This baseline assessment on the situation in the EU/EEA, despite its limitations due to its the response rate, provides invaluable information towards the development of a planned ECDC Guidance on testing helping to ensure that this new Guidance will focus on the main gaps identified.

Explore further: Taking stock: Where does Europe stand in the elimination of hepatitis B and C?

More information: ecdc.europa.eu/en/publications … af70113dbb90&ID=1706

Related Stories

Taking stock: Where does Europe stand in the elimination of hepatitis B and C?

March 2, 2017
In 2016, a regional action plan for Europe contributing to the implementation of the global viral hepatitis elimination strategy was developed by the WHO Regional Office for Europe. In an article published today in Eurosurveillance, ...

Antenatal screening in Europe: How to avoid mother-to-child transmission of infections

March 21, 2017
Transmission of infections with HIV, hepatitis B, syphilis or rubella from mother to child before and during birth as well as in infancy still occur across Europe - despite existing prevention methods. A new ECDC report outlines ...

Is Europe ready to eliminate viral hepatitis?

July 27, 2016
The goal for 2030: a world free of hepatitis. Currently, Europe records around 57 000 newly diagnosed acute and chronic cases of hepatitis B and C each year. On top of that, an estimated 10 million Europeans are believed ...

Hepatitis C increasing among pregnant women

May 11, 2017
Hepatitis C infections among pregnant women nearly doubled from 2009-2014, likely a consequence of the country's increasing opioid epidemic that is disproportionately affecting rural areas of states including Tennessee and ...

Testing for hepatitis C virus remains low among baby boomers

March 8, 2017
A Brief Report appearing in the American Journal of Preventive Medicine looks at testing rates for Hepatitis C virus (HCV) two years after the United States Preventive Services Task Force (USPSTF) recommended it for all baby ...

Researchers highlight need for better evidence to guide EU efforts to increase hep B+C testing

April 25, 2015
The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented ...

Recommended for you

Infants born to obese mothers risk developing liver disease, obesity

November 16, 2018
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers ...

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Antibiotic prescribing influenced by team dynamics within hospitals

November 15, 2018
Antibiotic prescribing by doctors is influenced by team dynamics and cultures within hospitals.

Zika may hijack mother-fetus immunity route

November 14, 2018
To cross the placenta, Zika virus may hijack the route by which acquired immunity is transferred from mother to fetus, new research suggests.

New research aims to help improve uptake of hepatitis C testing

November 14, 2018
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).

Maternally acquired Zika immunity can increase dengue disease severity in mouse pups

November 14, 2018
To say that the immune system is complex is an understatement: an immune response protective in one context can turn deadly over time, as evidenced by numerous epidemiological studies on dengue infection, spanning multiple ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.